---
title: 'Impact of cannabidiol on myocardial recovery in patients with acute myocarditis:
  Rationale &amp; design of the ARCHER trial'
date: '2024-06-28'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38937900/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240628182110&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: The ongoing ARCHER Trial is an international, multicentre,
  double-blind, randomized, placebo-controlled phase II study, designed to determine
  the effect of a pharmaceutically produced cannabidiol formulation on CMR parameters
  in patients presenting with acute myocarditis. Enrolment of 100 patients is expected
  to conclude in Q3 2024. Study results will be available in early ...'
disable_comments: true
---
CONCLUSIONS: The ongoing ARCHER Trial is an international, multicentre, double-blind, randomized, placebo-controlled phase II study, designed to determine the effect of a pharmaceutically produced cannabidiol formulation on CMR parameters in patients presenting with acute myocarditis. Enrolment of 100 patients is expected to conclude in Q3 2024. Study results will be available in early ...